Regeneron Reports Promising Phase 1/2 Data Of Lynozyfic In Newly Diagnosed Multiple Myeloma
I'm PortAI, I can summarize articles.
Regeneron Pharmaceuticals announced promising Phase 1/2 trial results for Lynozyfic in newly diagnosed multiple myeloma patients. The trial showed impressive efficacy, with 70% achieving very good partial response or better, and 95% of evaluable patients achieving minimal residual disease negative status. These findings were presented at the American Society of Hematology Annual Meeting, highlighting Lynozyfic's potential for durable outcomes in early treatment lines.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments